Cancer immunotherapy: predict outcomes better with combination biomarkers
Immunotherapies are amazing drugs against cancer. However, they still fail for too many patients. In this series of lectures, I present IMPRES and TIDE, two of the best predictors of cancer immunotherapy outcomes.
I also show an easy way to combine them and improve their predictions, using a combination biomarker. Finally, I make suggestions of practical ways to contribute to research on this topic.
Speaker: Mostapha Benhenda, bioinformatician at Melwy.com
You will receive the link to the lectures by registering to this event.